Physician profile
Shefali Chheda
NPI 1285624338
$516.00
in general payments reported to CMS, 2019-2025
11 companies · $39.37 in 2025
The $39.37 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.89 · 2020: $59.71 · 2021: $73.09 · 2022: $59.20 · 2023: $128 · 2024: $123 · 2025: $39.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $113.61 | 2019-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $93.00 | 2024-2025 | Qelbree |
| Corium, LLC | $57.87 | 2022-2024 | Azstarys |
| Biofire Diagnostics, LLC | $53.06 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.46 | 2021 | |
| Sanofi Pasteur INC. | $37.34 | 2019-2021 | |
| Alk-Abello, INC | $35.75 | 2023-2024 | Grastek, Odactra, Ragwitek |
| Cognoa, INC. | $30.66 | 2022 | |
| Glaxosmithkline, LLC. | $22.30 | 2025 | Rotarix, Bexsero, Pediarix |
| Merck Sharp & Dohme LLC | $18.67 | 2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Cranial Technologies, INC | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shefali Chheda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.